Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

Obinutuzumab, a B-cell depleting therapy, is being explored for reducing lupus nephritis risks, such as flare.

Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.

Using triple therapy with belimumab for initial lupus nephritis treatment was associated with early renal response in a study of real-world patients.

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today provided an update on recent and anticipated ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License ...

A new study found a high prevalence of chronic kidney disease (CKD) among people with systemic lupus erythematosus (SLE), including in people without a diagnosis of lupus nephritis (LN, lupus-related ...

The Lupus Foundation of America is pleased to offer Lupus Education for Nurses, an on-demand, CNE-accredited webinar. The course is focused on increasing nurses’ knowledge and understanding of lupus ...

Systemic Lupus Erythematosus, also called Lupus, is an autoimmune condition where the body starts attacking its own cells. It can involve multiple systems like the skin, kidney, joints, etc.

New York Liberty's Isabelle Harrison Is Raising Awareness About Her Brother's Struggle With Lupus NEW YORK (AP) — Isabelle Harrison always looked forward to going to Indiana to play no matter ...